NanoViricides shares are trading higher after the company announced that its proposal to perform a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for the Current Bundibugyo Ebolavirus has been approved by the Pillar Committee in Charge in the Democratic Republic of Congo.